Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
DZIF 2023
Programm
Poster
Personen
Suche
EN
Zurück
Postersession
Postersession I
Termin
Datum:
25.09.2023
Zeit:
17:30
–
19:15
Ort / Stream:
Foyer
Programm
Poster
P-1-1
The DZIF Transplant Cohort e.V.
Dr. Daniela Schindler (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-2
Antibiotic susceptibility study of carriage and clinical strains of N. meningitidis in the health districts of Kaya and Boussouma in the central-northern region of Burkina Faso from 2016-2017
Dr. Emmanuel SAMPO (Ouagadougou/ BF)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-3
Candida
expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions
Dr. Bastian Seelbinder (Jena/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-4
ULBP2-expressing HCMV mutants modulate NKG2D expression and function on NK and CD8
+
T cells
Greta Meyer (Hannover/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-5
The added value of (1,3)-β-D-glucan for the diagnosis of Invasive Candidiasis in ICU patients: a prospective cohort study
Dr. Flaminia Olearo (Hamburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-6
SARS-CoV-2 induced B cells generate an anticipatory memory against new virus variants and re-engage in COVID-19 vaccine responses
Dr. Matthias Bruhn (Hannover/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-7
Outer membrane vesicle of
Klebsiella pneumoniae
decrease bactericidal properties of alveolar macrophages
Dr. Mohammad Estiri (Giessen/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-8
Invasive fungal disease in chronic liver transplant failure – an underestimated burden
Aleksandra Puzalkova (Heidelberg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-9
Interim analysis of a longitudinal study on sexual health in females
Dr. Nadja Käding (Lübeck/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-10
FGS and HPV prevalence and risk factors in rural Madagascar: implications for women's health services in limited resource settings
Jean-Marc Kutz (Hamburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-11
Microbiota context dependent dual protective role of Klebsiella oxytoca against Salmonella infection
Dr. Lisa Osbelt (Braunschweig/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-12
Plasma protein signature reveals chronic-inflammatory and angiogenic processes in addition to sustained immune cell differentiation in convalescent severe COVID-19 patients
Dr. Jenny Franziska Kühne (Hannover/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-13
The sporulation pathway as a pathoblocker target in
Clostridioides difficile
Christopher Birk (Würzburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-14
Pulmonary nucleotide transfection for antiviral therapy
Achim Biesel (Saarbrücken/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-15
Complex in vitro models and advanced delivery systems for improving drug transport across biological barriers delimiting bacterial bioavailability of anti-infective drugs
Prof. Dr. Claus-Michael Lehr (Saarbrücken/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-16
Interferon-Gamma-Release-Assay (IGRA) is a reliable and cost-effective method for the determination the T-cell immune response against SARS-CoV-2 directly ex vivo
Marta Minic (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-17
Potentiating the efficacy of antibiotics in Escherichia coli by nanorods
Mohamed Ashraf Mostafa Kamal (Saarbrücken/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-18
Human induced pluripotent stem cell (hiPSC‐) -derived lung organoids for disease modelling
Margarida Maria Barroso (Giessen/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-19
Neutrophil efferocytosis reprograms mitochondrial metabolism to lock alveolar macrophages in a pro-resolution phenotype at the expense of bacterial control
Dr. Julian Better (Marburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-20
Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: a scoping review
Lydia Holtgrewe (Heidelberg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-21
Assessing dynamics of respiratory syncytial virus from 2020-2022/23 in Germany in an epidemic panel (MuSPAD)
Dr. Manuela Harries (Braunschweig/ DE)
Dr. Carolina J. Klett-Tammen (Braunschweig/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-22
The role of paleoviral sequences of Ebola virus in immune tolerance
Christoph Henkel (Hamburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-23
A targeted mutagenesis screen of the hepatitis B virus envelope protein L implicates a structurally important domain for fusion
Dr. Britta Möhl-Meinke (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-24
EVREA-Phage: eradication of intestinal vancomycin resistant
Enterococcus faecium
through phage therapy
Dr. Filipa Martins (Braunschweig/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-25
Fever in focus: sex differences among pediatric fever visits in a Ghanaian birth cohort
Lydia Rautman (Hamburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-26
Generation of monoclonal antibodies targeting fiberknob that neutralize HAdV-5 infection
Dr. Britta Möhl-Meinke (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-27
Next generation of LMP2A-targeting engineered TCR-recombinant T cells with inducible expression of IL-18 as promising approach for EBV-associated malignancies
Philip Mausberg (Hannover/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-28
Overcoming immune escape in EBV-associated malignancies by understanding the two levels of immunosuppression: the tumor microenvironment and iatrogenic immunosuppression
Sven Stoll (Hannover/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-29
Evaluation von Diagnostik und Therapie der Pneumonie zur Verbesserung der Behandlungsqualität
David Leber (Hamburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-30
Genome-wide association analysis identifies three loci and one HLA allele associated with post-TB lung function in African adults
Luming Lin (Munich/ DE)
Kathrin Held (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-31
Analysis of transcriptional changes upon Respiratory Syncytial Virus infection of human airway epithelial cells
Dr. Sibylle Haid (Hannover/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-32
Assessing the activation profile of
Mycobacterium tuberculosis
-specific T cells as a surrogate marker for
in vivo
disease activity in tuberculosis household contacts
Kathrin Held (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-33
Impact of non-selective beta-blockers on the development of spontaneous bacterial peritonitis (SBP), hepatic decompensation and survival after transjugular intrahepatic portosystemic shunt (TIPS-) insertion
Prof. Benjamin Maasoumy (Hannover/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-34
Untangling the complex relationship between cytomegalovirus and tuberculosis in children investigated for TB
Alia Razid (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-35
Comparative mathematical model of RSV infection: pre, during, and post COVID-19 pandemic analysis in Germany
Dr. Isti Rodiah (Braunschweig/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-36
Scenarios for the SARS-CoV-2 pandemic 2023 in Germany
Dr. Isti Rodiah (Braunschweig/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-37
Impact of mucosal adjuvants on gut microbiome composition in prophylactic vaccination strategies against H. pylori.
Dr. Dharmesh Singh (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-38
A combination of direct acting and host-directed antivirals dramatically suppresses SARS-CoV-2 and MERS-CoV replication
Lucie Sauerhering (Marburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-39
Brain specific immune responses to Nipah- and Ebola virus infection in
in-vitro
and
ex-vivo
models
Dr. Alexandra Kupke (Marburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-40
Establishment and characterization of lethal and non-lethal animal models for Marburg virus
Michael Klüver (Marburg/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-41
Clinical signs of early inflammation can predict a prolonged course of Infectious Mononucleosis in children, adolescents, and young adults – data from a prospective clinical observational study in Germany (IMMUC study)
Kirstin Mittelstraß (Munich/ DE)
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
Poster
P-1-42
Improved clinical outcome of Covid-19 in haematologic malignancy patients receiving a fourth dose of anti-SARS-Cov-2 vaccine: an epicovideha report
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-43
Molnupiravir compared to nirmatrelvir/ritonavir for Covid-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the epicovideha registry
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-44
Nirmatrelvir/ritonavir in Covid-19 patients with haematological malignancies: a report from the epicovideha registry
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-45
Pre-exposure immunization by tixagevimab/cilgavimab in hematological malignancy and Covid-19 in the epicovideha registry
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-46
The current state of laboratory mycology in Asia/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-47
Laboratory capacities to diagnose and treat invasive fungal infections in Europe: results from the ECMM survey
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-48
Immunogenicity and reactogenicity of a first booster with BNT162B2 or full-dose of MRNA-1273: a randomised trial in adults ≥75 years (EU-COVAT-1) from the vaccelerate consortium
Dr. Philipp Koehler (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-49
Multipathogen antigen test kit (MAK-5) - distribution and frequency of viral respiratory diseases in Germany among volunteers in the vaccelerate registry
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-50
Poliovirus vaccination status among adult participants in the vaccelerate volunteer registry
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-51
Establishing the vaccelerate site network: capacity mapping of clinical trial sites
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-52
The first two years of the European vaccelerate volunteer registry
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-53
Country-specific needs, ethics and regulatory requisites related to implementing a trial volunteer registry across Europe: the vaccelerate volunteer registry experience
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-54
The Argentinian Landscape of mycological diagnostic capacity and treatment
Fernando Riera (Córdoba/ AR)
Immune Prevention and Therapy
Poster
P-1-55
Laboratory capacities to diagnose and treat invasive fungal infections in Austria, Germany and Switzerland
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-56
Laboratory capacities to diagnose and treat invasive fungal infections in Italy: local results from an ECMM survey
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-57
Laboratory capacities to diagnose and treat invasive fungal infections in Nordic countries: results from an NSMM and ECMM survey
Dr. Jon Salmanton-García (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-58
Targeting
Pseudomonas aeruginosa
LasB by patient-derived monoclonal antibodies
Dr. Alexandra Albus (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-59
A novel high-throughput Haemagglutinin binding assay to generate comprehensive Influenza virus escape maps
Leon Ullrich (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-60
Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escape
Dr. Christoph Kreer (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-61
Recombinant mosaic HBV capsid particles foster adaptive immunity against the most prevalent HBV genotypes by therapeutic vaccination
Shubhankar Ambike (Munich/ DE)
Immune Prevention and Therapy
Poster
P-1-62
RNA aptamers derived from the Hepatitis B Virus RNA element epsilon efficiently inhibit HBV replication in vitro
Dr. Jürgen Beck (Freiburg/ DE)
Immune Prevention and Therapy
Poster
P-1-63
HCMV neutralization by broad antibody targeting
Dr. Matthias Zehner (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-64
NRF2-independent inhibition of human coronaviruses by "NRF2 activators"
Dr. Fakhar Waqas (Hannover/ DE)
Immune Prevention and Therapy
Poster
P-1-65
Identification of human antibodies enhancing the innate immune response against
Pseudomonas aeruginosa
Julia Kutschera (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-66
Characterization of human papillomavirus-derived peptide binding to HLA in acidic tumor milieu
Dr. Maria Bonsack (Heidelberg/ DE)
Immune Prevention and Therapy
Poster
P-1-67
Longitudinal Dynamics Of SARS-CoV-2 Spike-specific Antibody Responses In Patients On Waiting List And After Lung Transplantation
Dr. Jenny Franziska Kühne (Hannover/ DE)
Immune Prevention and Therapy
Poster
P-1-68
Duration of protection from pneumonia after pneumococcal vaccination in haemodialysis patients – interim analysis of the DOPPIO study
Dr. Sibylle C. Mellinghoff (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-69
Translation of advanced cell therapies for HIV-positive patients into the clinic
Dr. Lea Isabell Schwarze (Hamburg/ DE)
Immune Prevention and Therapy
Poster
P-1-70
Effects of bile acids on NK cells in HDV patients under Bulevirtide treatment
Po-Chun Chen (Hannover/ DE)
Immune Prevention and Therapy
Poster
P-1-71
Itaconate and its downstream product mesaconate exhibit overlapping and distinct immunometabolic effects in macrophage
Dr. Wei He (Braunschweig/ DE)
Immune Prevention and Therapy
Poster
P-1-72
Soluble immunological markers correlate with acute inflammation and clinical severity in severe hepatitis ("hepatitis flares")
Roni Souleiman (Hannover/ DE)
Immune Prevention and Therapy
Poster
P-1-73
Vaccine to Inhibit Autochthonous Transmission of Hepatitis (VaccinATE)
Isabella Hrabal (Greifswald - Insel Riems/ DE)
Immune Prevention and Therapy
Poster
P-1-74
Dual-active oxadiazoles targeting the
Mycobacterium tuberculosis
ESX-1 secretion system and boosting ethionamide activity
Dr. Michael Dal Molin (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-75
Blocking viral entry reduces the frequency of Hepatitis Delta virus infected hepatocytes in human liver biopsies
Dr. Lena Allweiss (Hamburg/ DE)
Immune Prevention and Therapy
Poster
P-1-76
Identification of a broad and potent NTD-targeting SARS-CoV-2 antibody using an extended pseudovirus panel
Finn Teipel (Cologne/ DE)
Immune Prevention and Therapy
Poster
P-1-77
Correlates of humoral immune protection in acute resolving and chronic HCV infection
Dr. Dorothea Bankwitz (Hannover/ DE)
Immune Prevention and Therapy
Poster
P-1-79
Intracellular mRNA:miRNA profiling after rVSV-ZEBOV vaccination
Monika Rottstegge (Hamburg/ DE)
Immune Prevention and Therapy
Poster
P-1-80
Pandemieimpfstoffherstellung in pandemiefreien Zeiten
Christian Marx (Langen/ DE)
Immune Prevention and Therapy
Poster
P-1-81
Innate immune modulation by HBV and HDV induced extracellular vesicles
Prof. Stephanie Jung (Bonn/ DE)
Chronic Infections
Poster
P-1-82
Preserved frequency and cytotoxicity of HIV-specific follicular CD8 T cells associates with reduced viral reservoir in individuals treated during primary HIV infection
PD Dr.med. Julia Roider (Munich/ DE)
Chronic Infections
Poster
P-1-83
Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions
Valerie Ohlendorf (Hannover/ DE)
Chronic Infections
Poster
P-1-84
Long-term outcome of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International Network (HDIN)
Dr. Anika Wranke (Hannover/ DE)
Chronic Infections
Poster
P-1-85
Prevalence, genotype distribution and risk factors of oropharyngeal human papilloma virus (HPV) infection over time in transplant recipients (DZIF-Transplantation Cohort)
PD Dr. Tina Ganzenmueller (Tübingen/ DE)
Chronic Infections
Poster
P-1-86
Multiplex serology to differentiate pan-hepatitis virus-specific antibody responses in vaccinated and infected individuals
Dr. Tanja Michel (Reutlingen/ DE)
Chronic Infections
Poster
P-1-87
Disrupting Kaposi's sarcoma-associated herpesvirus (KSHV) latent replication with a small molecule inhibitor and PROTACs
Aylin Berwanger (Saarbrücken/ DE)
Dr. Saskia C. Stein (Hannover/ DE)
Chronic Infections
Poster
P-1-88
HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection
Dr. Lisa Sandmann (Hannover/ DE)
Chronic Infections
Poster
P-1-89
NRF2 activators inhibit hepatitis E virus propagation in vitro
Fenja Laue (Hannover/ DE)
Chronic Infections
Poster
P-1-90
Ongoing low-level p24 production in long-term ART-treated individuals
Dr. Enrico Richter (Bonn/ DE)
Prof. Hendrik Streeck
Chronic Infections
Poster
P-1-91
An AAV-based RNAi and CRISPR vector system to multilaterally combat chronic HBV infections
Nico Fischer (Heidelberg/ DE)
Chronic Infections
Poster
P-1-92
High replication fitness of the hepatitis C virus, mediated by a small region in the non-structural protein 5A, is an evolutionary selection factor and causes direct viral pathogenesis in liver transplant patients
Prof. Dr. Volker Lohmann (Heidelberg/ DE)
Chronic Infections
Poster
P-1-93
Thioxothiazolo[3,4-a]quinazoline derivatives inhibit the human cytomegalovirus alkaline nuclease
Tianyu Zhang (Hamburg/ DE)
Chronic Infections
Poster
P-1-94
Latent CMV and SARS-CoV2: mutually detrimental or beneficial?
Dr. Upasana Kulkarni (Braunschweig/ DE)
Chronic Infections
Poster
P-1-95
The impact of cirrhosis on the regeneration of the inflammatory milieu after HCV cure
Moana Witte (Hannover/ DE)
Chronic Infections
Poster
P-1-96
A soluble plasma factor of post-COVID syndrome patients impairs innate immune signaling
Dr. Lea Picard (Cologne/ DE)
Chronic Infections
Poster
P-1-97
Vaginal microbiome variability in women affected by female genital schistosomiasis and human papillomavirus infection: a cross-sectional study from Madagascar
Jana Hey (Hamburg/ DE)
Chronic Infections
Poster
P-1-98
The impact of chronic schistosomiasis on co-infections with dengue virus in Madagascar
Jana Hey (Hamburg/ DE)
Chronic Infections
Poster
P-1-99
Polyfunctional hepatitis D virus-specific CD4
+
T-cell responses are detectable during low viremia time-points in patients chronically infected with the hepatitis D virus
Reem Hoblos (Hannover/ DE)
Dr. med. Helenie Kefalakes (Hannover/ DE)
Chronic Infections
Poster
P-1-100
Generation of a pan-genotypic MVA vector for targeting chronic hepatitis B via therapeutic vaccination
Dr. Anna D. Kosinska (Munich/ DE)
Chronic Infections
Poster
P-1-101
Altered immune cell phenotype in the gut associated lymphatic tissue (GALT) of post-Covid patients: implications for pathogenesis
Dr. Lea Picard (Cologne/ DE)
Chronic Infections
Poster
P-1-102
HBV RNA in the natural course of HBV/HDV coinfection
Dr. Lisa Sandmann (Hannover/ DE)
Chronic Infections
Poster
P-1-103
DNA methyltransferase inhibition improves the effect of immune checkpoint inhibitors to restore exhausted HBV-specific T cell responses
Melanie Urbanek-Quaing (Hannover/ DE)
Chronic Infections
Poster
P-1-104
Single cell analysis of hepatitis C virus (HCV) and heterologous virus-specific CD8+ T cell responses in patients with chronic HCV infection
Jasmin Mischke (Hannover/ DE)
Chronic Infections
Poster
P-1-105
Elevated levels of genome replication of Hepatitis C Virus are associated with response to interferon treatment but do not correlate with viral serum titers or DAA therapy failure
Tomke Arand (Heidelberg/ DE)
Chronic Infections
Poster
P-1-106
Strong reduction of HDV infected cells in HBV/HDV infected humanized mice receiving pegylated interferon-alpha in combination with Bulevirtide
Dr. Tassilo Volz (Hamburg/ DE)
Chronic Infections
Poster
P-1-107
Klebsiella pneumoniae
brain abscess caused by dissemination of a virulent subpopulation from a urinary tract infection
Prof. Dr. Christoph Ernst (Cologne/ DE)
Chronic Infections
Poster
P-1-108
First-in-class LMP1-TRAF2 interaction inhibitors block Epstein-Barr virus oncoprotein LMP1-induced signaling and interfere with LCL and PTLD survival
Fabian Giehler (Neuherberg/ DE)
Chronic Infections
Poster
P-1-109
The optimized LMP1-TRAF2 inhibitor lead compound SBL563 blocks LMP1 signaling and promotes cell death in EBV-induced tumor cells with high efficiency
Alice Randon (Neuherberg/ DE)
Chronic Infections
Poster
P-1-110
In depth characterization of follicular HIV-specific CD8 T cells in human peripheral blood
Danni Wang (Munich/ DE)
Chronic Infections
Poster
P-1-111
CD39 expression identifies tissue-resident CD8+ T cells with exhausted phenotype in lymph nodes of untreated HIV-positive individuals
Leon Cords (Hamburg/ DE)
Chronic Infections
Poster
P-1-112
Prevalence of HCV infections in Germany from an epidemic panel (MuSPAD)
Zahra Ghodratian (Frankfurt a. M./ DE)
Chronic Infections
Poster
P-1-113
Establishment and clinical validation of a laboratory developed hexaplex digital PCR assay for absolute quantification of EBV, CMV, VZV, HSV 1, HSV 2 and beta-globin from human tissue samples
Lisa Sophie Pflüger (Hamburg/ DE)
Chronic Infections
Poster
P-1-114
Neutrophil associated markers to predict postTB lung impairment
Christoph Leschczyk (Borstel/ DE)
Chronic Infections
Poster
P-1-115
HBV-specific T cell immunity in tissue and circulation: a system level analysis
Sainitin Donakonda (Munich/ DE)
Chronic Infections
Poster
P-1-116
High resolution MALDI MS Imaging in tuberculosis research – investigation of drug distribution and granuloma-penetration of anti-tuberculosis drugs
Eva-Maria Stemp (Bayreuth/ DE)
Chronic Infections
Poster
P-1-117
Economic evaluation to inform target product profile development for tuberculosis treatment monitoring
Dr. Florian M. Marx (Heidelberg/ DE)
Chronic Infections
Poster
P-1-118
Predicting HCMV reactivation and acute graft versus host disease in HSCT patients
Penelope C. Kay-Fedorov (Hannover/ DE)
Chronic Infections
Poster
P-1-119
Novel Small Chemical Compounds Blocking Herpes Simplex Virus Assembly
Prof. Dr. rer. nat. Beate Sodeik (Hannover/ DE)
Chronic Infections
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz